Guangzhou Wondfo Biotech Co Ltd Asset Resilience Ratio
Guangzhou Wondfo Biotech Co Ltd asset resilience ratio. Guangzhou Wondfo Biotech Co Ltd (300482) has an Asset Resilience Ratio of 23.76% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Guangzhou Wondfo Biotech Co Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Guangzhou Wondfo Biotech Co Ltd (2015–2025)
Asset resilience ratio of Guangzhou Wondfo Biotech Co Ltd from 2015 to 2025. This chart shows how Guangzhou Wondfo Biotech Co Ltd's Asset Resilience Ratio has changed over time. Read 300482 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Guangzhou Wondfo Biotech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 300482 asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.60 Billion | 23.76% |
| Total Liquid Assets | CN¥1.60 Billion | 23.76% |
Asset Resilience Insights
- Good Liquidity Position: Guangzhou Wondfo Biotech Co Ltd maintains a healthy 23.76% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Guangzhou Wondfo Biotech Co Ltd Industry Peers by Asset Resilience Ratio
Compare Guangzhou Wondfo Biotech Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
L&C Bio Co. Ltd
KQ:290650 |
Medical Devices | 2.14% |
|
Applied BioCode
TW:6598 |
Medical Devices | 9.75% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Radiant Innovation
TWO:3373 |
Medical Devices | 0.82% |
|
Impedimed Ltd
AU:IPD |
Medical Devices | 46.15% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
Guangzhou Wondfo Biotech Co Ltd Asset Resilience Ratio by Year (2015–2025)
Guangzhou Wondfo Biotech Co Ltd asset resilience ratio by year from 2015 to 2025. The table below shows the annual Asset Resilience Ratio data for Guangzhou Wondfo Biotech Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 19.15% | CN¥1.26 Billion ≈ $185.03 Million |
CN¥6.60 Billion ≈ $966.03 Million |
+0.90pp |
| 2024-12-31 | 18.26% | CN¥1.31 Billion ≈ $191.15 Million |
CN¥7.15 Billion ≈ $1.05 Billion |
+5.74pp |
| 2023-12-31 | 12.52% | CN¥722.45 Million ≈ $105.72 Million |
CN¥5.77 Billion ≈ $844.58 Million |
-2.37pp |
| 2022-12-31 | 14.89% | CN¥938.07 Million ≈ $137.27 Million |
CN¥6.30 Billion ≈ $922.05 Million |
+3.09pp |
| 2021-12-31 | 11.79% | CN¥572.73 Million ≈ $83.81 Million |
CN¥4.86 Billion ≈ $710.56 Million |
+9.41pp |
| 2020-12-31 | 2.38% | CN¥102.60 Million ≈ $15.01 Million |
CN¥4.31 Billion ≈ $630.12 Million |
-1.00pp |
| 2019-12-31 | 3.38% | CN¥99.50 Million ≈ $14.56 Million |
CN¥2.94 Billion ≈ $430.80 Million |
+4.04pp |
| 2018-12-31 | -0.66% | CN¥-17.66 Million ≈ $-2.58 Million |
CN¥2.69 Billion ≈ $393.85 Million |
+2.28pp |
| 2017-12-31 | -2.94% | CN¥-49.75 Million ≈ $-7.28 Million |
CN¥1.69 Billion ≈ $248.00 Million |
-2.93pp |
| 2016-12-31 | -0.01% | CN¥-69.38K ≈ $-10.15K |
CN¥1.01 Billion ≈ $147.17 Million |
+0.00pp |
| 2015-12-31 | -0.01% | CN¥-60.83K ≈ $-8.90K |
CN¥798.57 Million ≈ $116.86 Million |
-- |
About Guangzhou Wondfo Biotech Co Ltd
Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, market, sale, and service of vitro diagnostic products in China. The company offers rapid test kits for COVID-19, drug of abuse, tumor, infectious disease, fertility, tumor marker, and sexually transmitted diseases; immunofluorescence platform for detecting cardiac, thyroid, rhe… Read more